H1 2025 revenues declined 1.5% year-over-year to €241.1M, with gross margin improving to 42.9% and adjusted EBITDA margin rising to 8.6%. New product launches and increased R&D investment supported a higher vitality index, while net debt rose to €18.3M.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.